Abstract
Introduction
Trastuzumab, a monoclonal antibody directed against HER2, the product of the c-erbB-2 proto-oncogene, has represented a major improvement in the treatment of the subset of 20%-30% human breast cancers with this genetic abnormality. Randomized studies in the metastatic and adjuvant settings have shown that the addition of trastuzumab to chemotherapy results in significant improvements in clinical This material is protected by U.S. Copyright law.
Unauthorized reproduction is prohibited. For reprints contact: Reprints@AlphaMedPress.com Montemurro, Donadio, Clavarezza et al. 319 www.TheOncologist.com outcomes, including overall survival [1] [2] [3] [4] . Yet, because of its nature of targeted therapy and the uncertainties on its exact mechanism of action, several issues, which have relevant clinical and pharmacoeconomic implications, remain unresolved. Trastuzumab as a single agent has a response rate that peaks at around 35% in appropriately selected metastatic breast cancer patients [5] . When added to chemotherapy in the same setting, the response rate is almost double, and survival is longer than with chemotherapy alone [1, 2] . Unfortunately, most of the metastatic patients, including those with an impressive tumor response, develop disease progression during treatment. Preclinical experiments showed that trastuzumab exerts a cytostatic, rather than a cytotoxic, action on HER2-positive breast cancer cells [6] . Its withdrawal results in cancer growth, which can be suppressed by reintroducing the monoclonal antibody. On the basis of these observations and on the results of the early clinical trials, there is consensus that, in a responding patient with metastatic breast cancer, trastuzumab should be continued at least until tumor progression. In contrast, whether to stop or continue trastuzumab in a patient showing disease progression while on treatment is a subject of controversy. Preclinical data demonstrated that trastuzumab has additive or even synergistic effects with most of the cytostatic agents that are active in the treatment of breast cancer, including taxanes, vinorelbine, platinum salts, and others [7, 8] . These data, coupled with the tolerability of trastuzumab, have suggested to clinicians that continuing trastuzumab and changing the companion cytostatic agent could be a reasonable option in patients progressing on trastuzumab-based therapy. A few retrospective analyses in patients with HER2-positive advanced breast cancer showed encouraging response rates and survival when, upon disease progression, trastuzumab was continued and patients received further chemotherapy [9] [10] [11] . One obvious flaw of these reports is that patients discontinuing trastuzumab because of serious trastuzumab-related toxicity, or those experiencing rapid disease progression during the initial trastuzumab-based therapy and unable to receive further anticancer therapy, were not considered. Therefore, an encouraging clinical outcome might be the result of a selection bias. Indeed, in a follow-up analysis of 42 patients enrolled in a phase II trial of docetaxel and trastuzumab [12, 13] , we observed that progressing patients who could receive additional anticancer treatments without trastuzumab had clinical outcomes that were in the range of patients continuing trastuzumab beyond disease progression. In the absence of data from a randomized trial, our aim was to describe patterns of disease progression and treatment in patients with HER2-positive advanced breast cancer receiving trastuzumab-based therapy. , and in patients with HER2-positive tumors by fluorescence in situ hybridization (FISH), respectively. The median time to progression was 9.0 months (95% CI, 7.4-11.5 months). Details of the first post-progression treatment were required, but investigators were invited to provide information on any further anticancer treatment the patient received until death or the end of follow-up. 
Patients and Methods

Statistical Analyses
In patients who progressed during the initial trastuzumabbased regimen, we studied the following outcomes: (a) response rate (RR) to the first post-progression treatment (CR plus PR), as reported by each investigator at each site; (b) overall survival (OS), which was calculated from the day of the first administration of trastuzumab-based therapy to the documented date of death; (c) time-to-second tumor progression (TT-SP), which was calculated from the date of the first progression on trastuzumab-based therapy to the date of documented further tumor progression, or death of the patient in the absence of tumor progression; (d) post-progression survival (PPS), which was calculated from the date of the first progression on trastuzumab-based therapy to the date of the documented death of the patient. Patients alive were censored at the date of the last follow-up contact. Survival analyses were conducted by the KaplanMeier method. Because of the retrospective nature of the analysis and the descriptive aim of this report, we did not perform statistical comparisons of the clinical outcomes in different patient subsets. Figure 1 shows the flowchart of events and patterns of treatment for the entire group of 184 patients. The median follow-up for all the patients was 17 months (range, 1-66 months). Eighteen patients (10%) discontinued trastuzumab in the absence of tumor progression either because of unacceptable toxicity or the patient's or treating physician's decision (median duration of trastuzumab therapy, 7 weeks; range, 1-155 weeks). A total of 132 patients progressed while on the initial trastuzumab-based regimen and 89 died of tumor progression. Notably, a subset of 21 (16%) patients experienced rapid progression and could receive only supportive care until death. Upon first progression, trastuzumab was continued in 40 and stopped in 71 patients (Table 3 and Table 4 ). In the former group, 12 patients with isolated central nervous system (CNS) progression received radiotherapy and continued trastuzumab alone. The other 28 received trastuzumab combined with chemotherapy (23 patients) or endocrine therapy (5 patients). In the latter group, 61 women received chemotherapy and 10 received 
Results
Discussion
Our retrospective analysis results in HER2-positive advanced breast cancer patients progressing during trastuzumab-based therapy suggest that clinical outcome was similar, regardless of whether trastuzumab was continued beyond progression. Three papers reported on retrospective analyses focusing on patients continuing trastuzumab beyond disease progression [9] [10] [11] . Those studies included patients who had received at least two subsequent trastuzumab-based regimens for metastatic disease. Fountzilas et al. [10] described the clinical outcome of 80 patients continuing trastuzumab beyond disease progression in combination with additional chemotherapy. The first postprogression treatment resulted in a 24% response rate and a median progression-free survival duration of 5.2 months, but tumor responses were also seen with subsequent trastuzumab-based lines of treatment [10] . In a similar retrospective analysis conducted in 105 patients, Gelmon et al. [9] reported a 32% response rate and a median progression-free survival of 24-30.5 weeks when either trastuzumab alone or combined with chemotherapy was administered as second- The Oncologist ® line treatment after failure of an initial trastuzumab-based regimen. The third paper reported the results of a companion treatment-extension trial of the H0648g pivotal randomized study of chemotherapy alone and chemotherapy plus trastuzumab in HER2-positive advanced breast cancer patients [1, 11] . This companion study allowed patients in the chemotherapy-alone arms to receive trastuzumab upon disease progression and patients in the chemotherapy plus trastuzumab arms to continue trastuzumab beyond disease progression. While the primary aim of the companion study was to assess the safety of trastuzumab administered for long periods of time, the authors also reported efficacy results. In 93 patients continuing trastuzumab beyond disease progression, the response rate was 11%, and the median duration of response was 6.7 months. Although all authors placed caution on the interpretation of these outcomes, their results probably supported the practice of continuing trastuzumab beyond progression. Indeed, a recent longitudinal cohort study showed that, in the U.S., as many as 76% of patients progressing during an initial trastuzumab-based regimen received trastuzumab plus another chemotherapy in the following line of chemotherapy outside clinical trials [14] .
Our paper and the others that we have discussed above share the common limitations of retrospective analyses. This approach cannot account for the selection bias that goes into individualized therapeutic decisions. For example, we found that women who continued trastuzumab beyond progression were younger and more likely to have achieved tumor response to the initial trastuzumab-containing regimen compared with patients stopping trastuzumab upon disease progression. This may reflect different attitudes of physicians toward particular subsets of patients, making comparisons between outcomes of patients receiving different treatments unreliable. Another limitation of our analysis comes from the long half-life of trastuzumab once the steady state has been reached [14] . As a consequence, even in patients discontinuing trastuzumab and receiving different anticancer agents, tumor response may still depend on potential additive or synergistic effects of the monoclonal antibody. With these limitations well in mind, however, we believe that our data provide some valuable information for the clinician, as well as implications for further research. First, chemotherapy without trastuzumab yielded reassuring results in terms of response rate and survival in patients who progressed on trastuzumab-based therapy. Breast cancer with HER2 amplification or overexpression has long been recognized as a biologically aggressive disease [15, 16] . Trastuzumabbased treatments have improved the prognosis for HER2-positive breast cancer, to the point that it might become www.TheOncologist.com better than that of HER2-negative tumors treated with the same chemotherapy [17] . It is thus commonly perceived that, after trastuzumab failure, HER2-positive metastatic breast cancer patients have few options left. However, our data show that, with the exception of patients with rapidly progressing disease, chemotherapy and endocrine therapy were active in a significant proportion of patients, apparently regardless of trastuzumab continuation. Second, similar to cytotoxic chemotherapy or endocrine therapy, for which progression during treatment denotes "chemoresistant" or "endocrine-resistant" disease, tumor progression during trastuzumab is likely to be sustained by specific mechanisms of resistance to this agent. Results of the recently completed adjuvant randomized trials [3, 4] will translate into a greater number of patients receiving trastuzumab as part of the treatment for early HER2-positive disease. Resistance to this agent will therefore become a relevant issue when deciding the therapeutic conduct in those patients who develop metastatic disease during or shortly after adjuvant treatment with trastuzumab. Unfortunately, despite several interesting hypotheses having been generated in preclinical and translational studies [18, 19] , resistance to trastuzumab has not yet been defined in patients. Results with lapatinib, a small-molecule dual inhibitor of both epidermal growth factor receptor 1 and HER2, in heavily pretreated patients with HER2-positive advanced breast cancer who had failed prior trastuzumabbased treatments [20] further confirm that resistance to trastuzumab develops in patients and that it could be potentially overcome by other targeting agents.
Third, and not less important, trastuzumab therapy is expensive [21] . Outside the use as first-line therapy in appropriately selected HER2-positive breast cancer patients, its cost-effectiveness is unknown and probably unfavorable.
Many authorities in the field of breast cancer have invoked appropriately designed randomized trials to define the optimal therapeutic approach in women with HER2-positive advanced breast cancer developing disease progression while on trastuzumab-based therapy. These trials should clarify clinical as well as biological and pharmaeconomic issues. Unfortunately, so far, the few initiatives that have been launched have failed to reach their goals because of insufficient accrual and possibly also because of patients' and doctors' biases toward continuing trastuzumab beyond progression [22] . At present, we are aware of only two active large trials that are randomizing patients progressing while on trastuzumab-based therapy to capecitabine alone or capecitabine plus trastuzumab [23] and to vinorelbine alone or vinorelbine plus trastuzumab [24] .
Conclusion
In summary, we showed that further lines of chemotherapy or endocrine therapy without trastuzumab yielded acceptable rates of disease control in HER2-positive advanced breast cancer patients progressing on trastuzumab-based therapy. Our data question the policy of continuing trastuzumab beyond disease progression. However, as they were generated from retrospective analyses, neither data for nor against the continuation of trastuzumab beyond progression should translate into clinical guidelines at the present time. In our opinion, clinicians facing therapeutic decisions should consider and discuss with their patients that continuation of trastuzumab beyond disease progression has theoretical but unproven efficacy and that disease control can be achieved with other anticancer treatments, even discontinuing trastuzumab. Patient expectations should also be taken into account, as well as additional costs and rare but potentially severe cardiac trastuzumab-related toxicity.
Efforts should be focused on completing the accrual of the ongoing randomized trials and on planning new initiatives in order to establish the correct strategy in this setting of patients. 324 Outcome Beyond Progression on Trastuzumab
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